CN107007623A - 一种治疗耳炎的复方汞溴红溶液及其制备方法 - Google Patents
一种治疗耳炎的复方汞溴红溶液及其制备方法 Download PDFInfo
- Publication number
- CN107007623A CN107007623A CN201710397167.XA CN201710397167A CN107007623A CN 107007623 A CN107007623 A CN 107007623A CN 201710397167 A CN201710397167 A CN 201710397167A CN 107007623 A CN107007623 A CN 107007623A
- Authority
- CN
- China
- Prior art keywords
- parts
- otitis
- merbromin
- liquor merbromin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 title claims abstract description 75
- 229960002782 merbromin Drugs 0.000 title claims abstract description 70
- 208000005141 Otitis Diseases 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 208000019258 ear infection Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title abstract description 8
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims abstract description 32
- 229960001907 nitrofurazone Drugs 0.000 claims abstract description 32
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims abstract description 26
- RXXROIWDLGTUIN-UHFFFAOYSA-N zinc;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide Chemical compound [Zn+2].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1.C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 RXXROIWDLGTUIN-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 17
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 13
- 229960004125 ketoconazole Drugs 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- KTCCKNDTESWMHC-UHFFFAOYSA-N [Br].[Hg] Chemical compound [Br].[Hg] KTCCKNDTESWMHC-UHFFFAOYSA-N 0.000 claims description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 241000894006 Bacteria Species 0.000 abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 24
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 16
- 229960001082 trimethoprim Drugs 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 14
- 229940124530 sulfonamide Drugs 0.000 description 14
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 206010033078 Otitis media Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940008716 mercurochrome Drugs 0.000 description 5
- 206010033072 otitis externa Diseases 0.000 description 5
- LBDIKIOMFGWKNT-UHFFFAOYSA-N pyrimidine;zinc Chemical compound [Zn].C1=CN=CN=C1 LBDIKIOMFGWKNT-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 4
- 229940092705 beclomethasone Drugs 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000726221 Gemma Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PCFUWBOSXMKGIP-UHFFFAOYSA-N 2-benzylpyridine Chemical compound C=1C=CC=NC=1CC1=CC=CC=C1 PCFUWBOSXMKGIP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000122862 Fonsecaea Species 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 108010014404 dihydrofolate synthetase Proteins 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- -1 sulphur Amine Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗耳炎的复方汞溴红溶液及其制备方法，所述复方汞溴红溶液包括如下重量份的原料：汞溴红溶液10‑20份、呋喃西林溶液0.1‑0.5份、磺胺嘧啶锌0.01‑0.5份、丙酸倍氯米松0.001‑0.01份。其制备方法为将磺胺嘧啶锌、丙酸倍氯米松以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。本发明将汞溴红溶液、呋喃西林溶液、磺胺嘧啶锌和丙酸倍氯米松进行科学配伍，毒性小，安全性高，既能够达到抗炎杀菌的治疗效果，又能对感染细菌皮肤的耐药菌起到抑制作用，疗效可靠，不复发。
Description
技术领域
本发明涉及一种治疗耳炎的药物，具体为一种对汞溴红溶液进行复配所得到的治疗耳炎的药物及其制备方法。
背景技术
汞溴红，有机化合物，即2,7-二溴-4-羟汞基荧光红双钠盐；又名红汞，带有绿色或蓝绿赤褐色的小片或颗粒，易溶于水，微溶于乙醇和丙酮，不溶于氯仿和乙醚，其水溶液呈樱红色或暗红色，适用于表浅创面皮肤外伤的消毒。
汞溴红2％的水溶液，俗称红药水，是古老的药物之一，对于小面积外伤具有显著的疗效，它的汞离子解离后与蛋白质结合，从而起到杀菌作用，但其杀菌作用较弱，对芽孢无效，目前治疗范围小，通常只用于外伤，小面积皮肤黏膜的消毒作用；除此之外由于汞是一种剧毒非必需元素，若正确使用，则是安全性比较高的外用消毒防腐剂，若使用不慎，将会产生较大的毒副作用，因此这无形给婴幼儿患者监护人或者大面积烧伤患者等人群造成了恐惧心理，进而限制了研究人员对汞溴红溶液的新开发和利用。
多年来耳炎是临床医生较为棘手疾病，常见的耳炎包括化脓性中耳炎、外耳道炎、外耳道真菌感染等，是全国常见病，相对也比较难治疗，多发于夏季，尤其是游泳或擦伤后，由于高温高湿会促使细菌或霉菌迅速生长，而霉菌植入皮肤角质层后会先处于潜伏期持续数天或数周，再侵入上皮表层而达增殖期引起炎症，在霉菌的植入期或潜伏期时均无症状，只有在增殖期时霉菌才会大量繁殖，并伴有大量上皮脱屑、耳痒、肿痛、溢脓、耳鸣、听力下降等症状，因此耳炎难以治疗，目前一直未有可靠的治疗方法。
将汞溴红溶液用于治疗外耳道炎、化脓性中耳炎等耳炎以控制病情在相关杂志文献有记载，但疗效欠佳，如中国耳鼻咽喉颅底外科杂志第3卷第1期1997年3月，复方汞溴红制剂治疗霉菌性外耳道炎，其组方为氯霉素、地塞米松、乙醇、甘油等，该组方对耳炎初期疗效较好，但是组方复杂，易于复发，疗效欠佳。
发明内容
为了解决现有技术存在的上述问题，本发明提供了一种治疗耳炎的复方汞溴红溶液及其制备方法，本发明所提供的治疗耳炎的复方汞溴红溶液毒性小，既能够达到的治疗效果，又能对感染细菌皮肤的耐药菌起到抑制作用，本发明的复方汞溴红溶液组方简单，疗效俱佳，其制备方法简单，使用方便，疗效可靠。
一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：
汞溴红溶液10-20份、呋喃西林溶液0.1-0.5份、磺胺嘧啶锌0.01-0.5份、丙酸倍氯米松0.001-0.01份。
本发明以汞溴红溶液作为溶媒，添加呋喃西林溶液、磺胺嘧啶锌和丙酸倍氯米松进行增效抗菌，可以治疗化脓性中耳炎、外耳道炎、外耳道搔痒症等炎症，将本发明的复方汞溴红溶液滴于耳朵发炎处，可清洗病灶，消除异物，本发明的复方汞溴红溶液具有消炎、收敛、解毒消腐的作用。其中的呋喃西林能干扰细菌的糖代谢过程和氧化酶系统而发挥抑菌或杀菌作用，主要干扰细菌糖代谢的早期阶段，导致细菌代谢紊乱而死亡。其抗菌谱较广，对多种革兰阳性和阴性菌有抗菌作用，对厌氧菌也有作用，对假单孢菌属及变形杆菌属有耐药性，对因霉菌引起的细菌感染有相当效力，呋喃西林即使处于存在脓液的情况下也可被皮肤吸收从而起到抗炎的疗效；
磺胺嘧啶锌为局部应用磺胺药，具有磺胺嘧啶和锌两者的作用，对多数革兰阳性菌、革兰阴性菌、酵母菌和其他真菌均有良好抗菌作用，且不被对氨基苯甲酸所拮抗，其中锌因能破坏细菌的DNA结构，亦具有抑菌作用，因此磺胺嘧啶锌可补偿患者的锌损失，并增强机体抵抗感染和创面愈合能力；
丙酸倍氯米松系强效外用糖皮质激素类药，具有抗炎、抗过敏和止痒等作用，局部抗炎作用是肤轻松和去炎松等同类药物的5倍，其亲脂性较强，易渗透，涂于患处30分钟后即可生效，丙酸倍氯米松对体温和排尿也无明显影响，因此，局部外用不会抑制人体皮质功能和因皮质功能紊乱所引起的不良反应。
本发明按上述重量份将汞溴红溶液、呋喃西林溶液、磺胺嘧啶锌和丙酸倍氯米松进行科学配伍，毒性小，安全性高，既能够达到抗炎杀菌的治疗效果，又能对感染细菌皮肤的耐药菌起到抑制作用，疗效可靠，不复发。
优选地：一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：汞溴红溶液15-20份、呋喃西林溶液0.1-0.3份、磺胺嘧啶锌0.01-0.1份、丙酸倍氯米松0.001-0.005份。
优选地：一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：汞溴红溶液20份、呋喃西林溶液0.1份、磺胺嘧啶锌0.01份、丙酸倍氯米松0.001份。
优选地：所述汞溴红溶液的质量百分浓度为2％；所述呋喃西林溶液的质量百分浓度为2％。
优选地：所述治疗耳炎的复方汞溴红溶液还包括0.001-0.01重量份的甲氧苄啶。
为了进一步增加本发明的疗效，提高其抗菌性，在配方中添加甲氧苄啶，其中甲氧苄啶的作用机理为：甲氧苄啶是细菌二氢叶酸还原酶抑制剂，属磺胺增效药，其抗菌谱与磺胺药类似，有抑制二氢叶酸还原酶的作用，但细菌较易产生耐药性，很少单独使用，而磺胺药则抑制二氢叶酸合成酶，将两者合用，可使细菌的叶酸代谢受到双重阻断，因而抗菌作用大幅度提高(可增效数倍至数十倍)，故有磺胺增效剂之称，并可减少抗药菌株的出现。
动力学显示甲氧苄啶口服吸收完全，可达给药量的90％以上，吸收后广泛地分布于全身的组织和体液中，可穿过血脑屏障，在脑膜炎症时脑脊液药物浓度可达血液浓度的50-100％，可穿过胎盘进入胎儿体内，胎儿循环血药浓度与母体血浓度相近，该品主要经肾排泄，24h尿中排出量为给药量的40-60％：其中80-90％以药物原形排出，该品t1/2为8-10h。
进一步地：所述治疗化脓性中耳炎的复方汞溴红溶液还包括0.1-0.5重量份的酮康唑。
由于部分呈弥漫潮红肿胀的耳道皮肤会伴有少量的分泌物，这些分泌物会培养以念珠菌、茀状菌、青霉菌金黄色葡萄球菌、绿脓杆菌等真菌，随着真菌的繁殖进一步反复引起炎症，针对此种真菌感染症状，作为优选，在配方中添加酮康唑，酮康唑属吡咯类抗真菌药，对深部感染真菌如念珠菌属、着色真菌属、球孢子菌属、组织浆胞菌属、孢子丝菌属等均具抗菌作用，对毛发癣菌等亦具抗菌活性，酮康挫药理作用为通过干扰细胞色素P-450的活性，从而抑制真菌细胞膜主要固醇类-麦角固醇的生物合成，损伤真菌细胞膜并改变其通透性，以致重要的细胞内物质外漏，酮康挫可抑制真菌的三酰甘油和磷脂的生物合成，抑制氧化酶和过氧化酶的活性，引起细胞内过氧化氢积聚导致细胞亚微结构变性和细胞坏死，对白念珠菌则可抑制其自芽孢转变为侵袭性菌丝的过程。
在本发明中添加酮康挫可有效治疗外耳道真菌感染等症状。
更进一步地：所述磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶和酮康唑的粒径均小于0.2mm。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括：将上述重量份的磺胺嘧啶锌、丙酸倍氯米松以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括：将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括：将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶、酮康唑以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。
本发明的有益效果为：
本发明将汞溴红溶液、呋喃西林溶液、磺胺嘧啶锌和丙酸倍氯米松进行科学配伍，毒性小，安全性高，既能够达到抗炎杀菌的治疗效果，又能对感染细菌皮肤的耐药菌起到抑制作用，疗效可靠，不复发。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚，下面将对本发明的技术方案进行详细的描述。显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式，都属于本发明所保护的范围。
下面实施例中以1份代表1g。
实施例1
一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：
2wt％的汞溴红溶液10份、2wt％的呋喃西林溶液0.1份、磺胺嘧啶锌0.01份、丙酸倍氯米松0.001份。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括将上述重量份的磺胺嘧啶锌、丙酸倍氯米松分别粉碎至粒径为0.2mm的颗粒，然后进行混合，得第一物料，将所述第一物料与上述重量份的2wt％的呋喃西林溶液分别置入2wt％的汞溴红溶液混合搅拌，直至完全溶解，即得。
实施例2
一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：
2wt％的汞溴红溶液17份、2wt％的呋喃西林溶液0.15份、磺胺嘧啶锌0.3份、丙酸倍氯米松0.002份、甲氧苄啶0.003份。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶分别粉碎至粒径为0.18mm的颗粒，然后进行混合，得第一物料，将所述第一物料与上述重量份的2wt％的呋喃西林溶液分别置入2wt％的汞溴红溶液混合搅拌，直至完全溶解，即得。
实施例3
一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：
2wt％的汞溴红溶液20份、2wt％的呋喃西林溶液0.1份、磺胺嘧啶锌0.01份、丙酸倍氯米松0.001份、甲氧苄啶0.001份、酮康唑0.1份。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶、酮康唑分别粉碎至粒径为0.15mm的颗粒，然后进行混合，得第一物料，将所述第一物料与上述重量份的2wt％的呋喃西林溶液分别置入2wt％的汞溴红溶液混合搅拌，直至完全溶解，即得。
实施例4
一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：
2wt％的汞溴红溶液18份、2wt％的呋喃西林溶液0.2份、磺胺嘧啶锌0.4份、丙酸倍氯米松0.003份、甲氧苄啶0.006份、酮康唑0.3份。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶、酮康唑分别粉碎至粒径为0.14mm的颗粒，然后进行混合，得第一物料，将所述第一物料与上述重量份的2wt％的呋喃西林溶液分别置入2wt％的汞溴红溶液混合搅拌，直至完全溶解，即得。
实施例5
一种治疗耳炎的复方汞溴红溶液，包括如下重量份的原料：
2wt％的汞溴红溶液18份、2wt％的呋喃西林溶液0.4份、磺胺嘧啶锌0.045份、丙酸倍氯米松0.008份、甲氧苄啶0.008份、酮康唑0.4份。
一种制备所述治疗耳炎的复方汞溴红溶液的方法，步骤包括将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶、酮康唑分别粉碎至粒径为0.14mm的颗粒，然后进行混合，得第一物料，将所述第一物料与上述重量份的2wt％的呋喃西林溶液分别置入2wt％的汞溴红溶液中混合搅拌，直至完全溶解，即得。
本发明治疗耳炎的复方汞溴红溶液的使用方法为：
1、先采用过氧化氢清洗脓性分泌物(医用双氧水可杀灭肠道致病菌、化脓性球菌，一般用于物体表面消毒，这种尚未结合成氧分子的氧原子，具有很强的氧化能力，与细菌接触时，能破坏细菌菌体，杀死细菌)。
2、将复方汞溴红溶液滴3-5滴于耳朵炎症患处，隔日一次，直至自觉症状消失3-5日(刺激性弱于双氧水)。
患者治疗情况：
病例1
王先生，男40岁，机场物业，5年前足疗后，做耳烛保健后奇痒，多处求医未见好转。双耳痒而就诊。到我处进行诊断治疗，发现患者双侧外耳道有白色丝状物和干痂，被诊断为外耳道炎合并真菌感染，按上述治疗方法进行治疗时，发现第一天双侧滴双氧水后泡沫较多，随后进行治疗8次，治愈，未复发。
病例2
孙女士，住机场南楼，有化脓性中耳炎病史，听力障碍10余年，于2015年春出现听力下降加重和耳鸣的现象，于是到我处进行就诊，其症状为左侧外耳道布满灰色耵聍，双氧水浸泡后形成变乳白色，耵聍变为弹性，于是诊断为胆脂瘤型中耳炎，在治疗初期，经三次双氧水清洗后，进一步用碳酸氢钠注射液浸泡并清理脓性分泌物，见外耳道宽大畸形，后采用复方汞溴红溶液滴耳10余次治愈，现一直未复发。
·病例3
·肖女士，36岁，住址北京西城，双朵流脓20余年，曾保守治疗无效后手术，2000年在某医院行乳突根治术，听力重建术，一年后复发。2015年7月，到我处就诊。症状为双侧外耳道脓性分泌物，外耳道宽大，精神状态欠佳，手脚凉，体质寒，确诊为术后复发患者，治疗过程为：先用双氧水冲洗双侧外耳道脓性分泌物，再用复方汞溴红溶液滴耳2个月，在第一周内一日一次，第二周开始隔日或2日一次，2周后一周两次，2个月后治愈，辅助检查无异常，无其他慢性病，至今未复发。
以上所述，仅为本发明的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，可轻易想到变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应以所述权利要求的保护范围为准。
Claims (10)
1.一种治疗耳炎的复方汞溴红溶液，其特征在于，包括如下重量份的原料：
汞溴红溶液10-20份、呋喃西林溶液0.1-0.5份、磺胺嘧啶锌0.01-0.5份、丙酸倍氯米松0.001-0.01份。
2.根据权利要求1所述的治疗耳炎的复方汞溴红溶液，其特征在于，包括如下重量份的原料：
汞溴红溶液15-20份、呋喃西林溶液0.1-0.3份、磺胺嘧啶锌0.01-0.1份、丙酸倍氯米松0.001-0.005份。
3.根据权利要求2所述的治疗耳炎的复方汞溴红溶液，其特征在于，包括如下重量份的原料：
汞溴红溶液20份、呋喃西林溶液0.1份、磺胺嘧啶锌0.01份、丙酸倍氯米松0.001份。
4.根据权利要求1-3中任一项所述治疗耳炎的复方汞溴红溶液，其特征在于，所述汞溴红溶液的质量百分浓度为2％；所述呋喃西林溶液的质量百分浓度为2％。
5.根据权利要求1-3中任一项所述治疗耳炎的复方汞溴红溶液，其特征在于，所述治疗耳炎的复方汞溴红溶液还包括0.001-0.01重量份的甲氧苄啶。
6.根据权利要求5所述的治疗耳炎的复方汞溴红溶液，其特征在于，所述治疗耳炎的复方汞溴红溶液还包括0.1-0.5重量份的酮康唑。
7.根据权利要求6所述的治疗耳炎的复方汞溴红溶液，其特征在于，所述磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶和酮康唑的粒径均小于0.2mm。
8.一种制备如权利要求1-3中任一项所述治疗耳炎的复方汞溴红溶液的方法，其特征在于，步骤包括：将上述重量份的磺胺嘧啶锌、丙酸倍氯米松以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。
9.一种制备如权利要求5所述治疗耳炎的复方汞溴红溶液的方法，其特征在于，步骤包括：将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。
10.一种制备如权利要求6或7所述治疗耳炎的复方汞溴红溶液的方法，其特征在于，步骤包括：将上述重量份的磺胺嘧啶锌、丙酸倍氯米松、甲氧苄啶、酮康唑以及呋喃西林溶液分别置入汞溴红溶液混合搅拌，直至完全溶解，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710397167.XA CN107007623A (zh) | 2017-05-31 | 2017-05-31 | 一种治疗耳炎的复方汞溴红溶液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710397167.XA CN107007623A (zh) | 2017-05-31 | 2017-05-31 | 一种治疗耳炎的复方汞溴红溶液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107007623A true CN107007623A (zh) | 2017-08-04 |
Family
ID=59451040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710397167.XA Pending CN107007623A (zh) | 2017-05-31 | 2017-05-31 | 一种治疗耳炎的复方汞溴红溶液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107007623A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101090707A (zh) * | 2004-12-09 | 2007-12-19 | 拜耳医药保健股份公司 | 用于在耳内卫生给药的药物 |
-
2017
- 2017-05-31 CN CN201710397167.XA patent/CN107007623A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101090707A (zh) * | 2004-12-09 | 2007-12-19 | 拜耳医药保健股份公司 | 用于在耳内卫生给药的药物 |
Non-Patent Citations (1)
| Title |
|---|
| 伍干元等: "复方汞溴红制剂治疗霉菌性外耳道炎", 《中国耳鼻咽喉颅底外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1740166B1 (en) | Therapeutic antimicrobial compositions and methods | |
| US8632823B2 (en) | Treatment of infected tissues with hypochlorous acid | |
| EP2525803B1 (en) | Antimicrobial agentcomprising peroxide, alcohol and chelating agent | |
| CN110917196B (zh) | 一种氯喹抑菌消毒液及其应用 | |
| CN101361790A (zh) | 治疗皮炎湿疹、蚊虫叮咬所致瘙痒药物及用途 | |
| CN106421217B (zh) | 一种苯扎氯铵的溶液及其制备方法 | |
| US7524512B2 (en) | Composition and method for the prevention and relief of the symptoms of an incompetent or patulous Eustachian tube | |
| US4708873A (en) | Method of chemically debriding uncerated necrotic tissue | |
| Mohr et al. | Neonatal case studies using active leptospermum honey | |
| CN108420789B (zh) | 一种苯扎氯铵外用溶液及其制备方法 | |
| CN108926577A (zh) | 一种电位水用于伤口抗菌愈合清洁护理的方法 | |
| CN107519236A (zh) | 一种治疗灰指甲的外用药剂 | |
| KR101453834B1 (ko) | 생약재를 이용한 세정제 조성물 제조 방법 및 이를 이용한 세정제 조성물 | |
| CN107007623A (zh) | 一种治疗耳炎的复方汞溴红溶液及其制备方法 | |
| EP2965755A1 (de) | Verbindungen zur verwendung bei der behandlung von erkrankungen | |
| CN101972271B (zh) | 一种二氧化氯粘膜凝胶及其制备方法 | |
| West | A palliative approach to the management of malodour from malignant fungating tumours | |
| MYER III | Historical perspective on the use of otic antimicrobial agents | |
| JPH10236961A (ja) | 電解酸性水を用いた眼科用剤 | |
| CN112972516B (zh) | 一种用于外耳道炎的消毒产品 | |
| CN116115683B (zh) | 一种金银花抑菌液及其制备方法 | |
| CN117244009A (zh) | 一种新型耳道抑菌凝胶 | |
| EP4609853A1 (en) | Absorbable composition for regeneration of skin lesions | |
| Blayney et al. | Mastoid surgery in chronic granulomatous disease | |
| MX2007006334A (es) | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170804 |